



Pancreatic Exocrine Insufficiency

Part 1 of 2: Pathogenic and Diagnostic Considerations



SHADEAH LAILA SULEIMAN
VIVEK KADIYALA, MD
DARWIN L. CONWELL, MD, MS

*Center for Pancreatic Disease
Brigham and Women's Hospital
Division of Gastroenterology,
Hepatology, and Endoscopy
Harvard Medical School
Boston, Massachusetts*

In this 2-part review, Part 1 covers the epidemiologic factors, pathogenic mechanisms, and current diagnostic strategies of pancreatic exocrine insufficiency (PEI); Part 2 will cover treatment approaches for patients with PEI, including the proper use of currently FDA-approved pancrelipase preparations.

In this 2-part review, Part 1 covers the epidemiologic factors, pathogenic mechanisms, and current diagnostic strategies of pancreatic exocrine insufficiency (PEI); Part 2 will cover treatment approaches for patients with PEI, including the proper use of currently FDA-approved pancrelipase preparations.

The exocrine pancreas plays an essential physiologic role in maintaining digestive health, nutrition, and proper patterns of growth. Pancreatic exocrine secretion of digestive enzymes breaks down ingested food into micronutrients for absorption into the circulatory system. A disruption of this process by pancreatic ductal blockage, parenchymal destruction, or surgical resection may lead to PEI. Vulnerable patients who have lost more than 90% of pancreatic function exhibit steatorrhea and are at risk for short- and long-term nutritional deficiencies and complications that compromise clinical outcomes.¹

Utilization of pancreas function tests in at-risk patients allows for accurate diagnosis of PEI, which is critical to initiating effective disease management and limiting complications of maldigestion. Although dietary modifications are helpful, most patients with PEI require individualized, lifelong support with pancreatic enzyme replacement therapy (PERT). Proper dosage, timing, and adherence to exogenous pancreatic enzyme replacements are essential to optimize efficacy and minimize adverse effects that may impact life expectancy and patient quality of life. Improper use of PERT by clinicians or patients may also exacerbate disease complications, increasing healthcare expenditures and the overall economic burden of PEI.

Epidemiology and Burden of PEI

PEI develops most commonly in children with cystic fibrosis (CF) or adults with advanced-stage chronic pancreatitis (CP).² As shown in the Table, other causes of pancreatic exocrine dysfunction include pancreatic diseases such as hereditary pancreatitis, tropical pancreatitis, severe acute necrotizing pancreatitis, acute recurrent pancreatitis, and chronic main pancreatic duct obstruction, including pancreatic cancer. Metabolic disorders, such as hypercalcemia and hyperlipoproteinemia;² extrapancreatic illnesses, such as celiac disease, Crohn's disease, primary biliary cirrhosis, and sclerosing cholangitis; and, rarely, isolated enzyme deficiencies observed in pediatric patients have been associated with PEI.^{3,4} PEI is also common after pancreatic and gastric surgical procedures, notably including pancreatic resection. The clinical and economic burden attributable to PEI is difficult to determine and has not been clearly established in medical literature. However, since individuals with CF and CP require PERT to remedy enzyme insufficiencies,⁵⁻⁷ PEI prevalence and costs can be extrapolated from epidemiologic data available for CF and CP patient populations.

CYSTIC FIBROSIS

CF is the most common lethal genetic defect occurring in the Caucasian population.⁸ The global incidence of CF varies among races, and in the United States

ranges from 1 in 2,500 to 1 in 3,500 live births in the Caucasian population.^{8,9} CF currently affects approximately 30,000 adults and children in the United States.¹⁰ Although the cost of care is variable, the mean annual cost of care for a patient with CF has been estimated at \$7,524.⁹

CF is inherited in an autosomal recessive pattern localized to chromosome 7, which encodes the cystic fibrosis transmembrane conductance regulator (CFTR). Dysfunction of CFTR leads to the clinical manifestations of CF.¹¹ Although the pulmonary complications are more evident, in the pancreas this mutation alters chloride transport from pancreatic ductal cells causing viscous proteinaceous secretions which block the pancreas ducts. This eventually leads to scarring and progressive pancreatic insufficiency.^{11,12} Other common gastrointestinal manifestations of CF include gastroesophageal reflux disease, small bowel overgrowth, rectal prolapse, hepatobiliary disease, intussusception, meconium ileus, and distal intestinal obstructive syndrome (DIOS).¹³

Approximately 50% of children with CF exhibit pancreatic insufficiency at birth, and another 25% develop pancreatic dysfunction within the first 6 months of life.^{14,15} Of the remaining 25% of children with CF, at least 15% will develop PEI later in childhood or young adulthood, leaving up to only 10% of children with CF who will have sufficient pancreatic activity for the duration of their lives.¹⁵ Although pancreatic sufficiency in CF patients is generally associated with better clinical outcomes, it does not imply normal pancreatic function and is still associated with a risk for developing DIOS or CF-related diabetes.^{13,16} It is estimated that more than 90% of children with CF require PERT as a life-sustaining intervention for PEI.¹⁷ Expected survival rates for individuals with CF has improved with the use of PERT, as well as advances in pulmonary care and recognition of early signs of malnutrition.¹⁸ The median age of survival for people with CF has risen to 37 years, with more than 40% of individuals with CF being 18 years of age or older.¹⁰ The rising life expectancy of individuals with CF augments the opportunity to effectively treat the disease and manage gastrointestinal symptoms as well as other associated sequelae (ie, metabolic bone disease).

CHRONIC PANCREATITIS

CP is caused by chronic inflammation of the pancreas associated with genetic, autoimmune, and environmental factors and occurs more frequently in male adults.² The incidence ranges from 3 to 9 cases per 100,000 individuals and increases with age.^{19,20} The data on prevalence is scarce but is estimated at 28.5 to 41.8 cases per 100,000 persons. The gradual rise in incidence observed in some countries may be attributed to earlier diagnosis and/or increasing alcohol consumption.^{19,21-23}

Table. Etiologies of Pancreatic Exocrine Insufficiency⁶⁹

Mechanism	Etiology
Decreased lipase production and delivery, increased lipase destruction	Chronic pancreatitis, cystic fibrosis, diabetes
Pancreatic duct obstruction	Periampullary tumor, pancreatic head cancer, IPMN, benign tumors
Decreased endogenous lipase stimulation and production	Celiac disease, Crohn's disease, Shwachman-Diamond syndrome
Motility disorders (decreased contact time, interaction with chyme, and stimulation of pancreatic enzymes)	Gastrectomy, gastric bypass, extensive small bowel resection

IPMN, intraductal papillary mucinous neoplasm

Alcohol abuse accounts for 70% to 80% of CP cases.²⁴ PEI and symptoms of maldigestion usually develop after approximately 10 to 15 years of chronic alcoholic abuse²⁵ and vary according to CP disease severity and duration; prevalence of PEI is estimated at 30% for mild CP and up to 85% for severe CP.²⁶ Idiopathic PEI accounts for 10% of adult CP cases.²⁵ Management of patients with CP involves significant annual healthcare expenditures, accounting for more than 122,000 outpatient visits and over 56,000 hospitalizations in the United States, with total treatment costs estimated at \$2.1 billion in 1998.^{27,28} Emerging epidemiological data from the North American Pancreatitis Study Group has improved our understanding of the etiologic factors at play in CP in the United States, implicating smoking as a dose-dependent, causal co-factor for CP. The combined effect of smoking and alcohol is synergistic and contributes profoundly to development and progression of the disease.

Pathogenesis of PEI

Loss of exocrine function in patients with CF and CP results from the inflammatory destruction of pancreatic ductal and acinar cells, causing a reduction in the quantity of enzymes available to digest carbohydrates, proteins, and fats and consequently resulting in maldigestion and malabsorption.

THE DIGESTIVE PROCESS AND FAT MALABSORPTION

Suboptimal carbohydrate, protein, and fat digestion processes underlie the clinical symptoms of PEI and are among the diagnostic criteria for the condition. Carbohydrate digestion starts in the mouth with salivary

amylase and continues at the brush border of the small intestine with both intestinal oligosaccharidases and pancreatic amylase secretions.²⁹ Protein digestion begins in the stomach with hydrochloric acid activation of pepsin and continues at the brush border with pancreatic and intestinal proteolytic enzymes.²⁹ Despite loss of pancreatic function, carbohydrate and protein digestion are well maintained in individuals with PEI, as the digestive system is capable of compensating for PEI. In contrast, lipid digestion involves a more complex, multistep process of emulsification and ultimately fatty acid hydrolysis, the latter process being highly dependent on pancreatic lipase. Thus, exogenous therapeutic intervention is necessary to rescue the functional deficiency.²⁹

In healthy individuals, dietary fat is first modified by lingual and gastric lipase in the stomach. Bile salts subsequently solubilize the lipolytic products through the formation of micelles for further hydrolysis in the small intestine by pancreatic lipase. Lipase then breaks down the lipids into long-chain fatty acids and monoglycerides in a neutralized chymal environment maintained by duct cell bicarbonate secretion.²⁹ Following absorption across the intestinal barrier, micelles are converted back into chylomicrons (lipoprotein particles), which circulate in the lymphatic system and return to the circulatory system for delivery to the body.²⁹

Fat absorption is particularly affected in individuals with PEI for several reasons.³⁰ The functional ability of the pancreas to synthesize and secrete lipase is impaired earlier and more severely than its other enzymes, particularly in the course of CP.³⁰⁻³² The pancreas is the primary source of lipase secretion for the digestion of

dietary fat, with intragastric lipase digestion accounting for approximately only 10% of total lipid digestion.²⁹ However, in patients with PEI, intragastric lipase digestion may account for more than 90% of total lipase activity but cannot compensate for loss of pancreatic lipase secretion.³³ Additionally, the insufficient pancreas does not secrete an adequate concentration of sodium bicarbonate, which protects pancreatic enzymes from denaturation by gastric acid and establishes an optimal pH (~8) for pancreatic enzyme activity. The resulting low duodenal pH impairs lipid solubilization by inactivating the bile acids, a complication further exacerbated by the denaturation of the pancreatic enzymes, notable at pH 5 or lower.^{34,35} Lastly, lipase is more susceptible to proteolytic degradation than other enzymes, including amylase.^{36,37} Lipase activity declines rapidly during small intestinal transit and is active for relatively short periods of time in both healthy individuals and patients with PEI.³⁶⁻³⁸ Thus, lipolysis is a complicated process for which pancreatic secretion of bicarbonate and lipolytic enzymes is essential and, once impaired, results in maldigestion and malabsorption, necessitating extrinsic pancreatic enzyme supplementation.

SIGNS AND SYMPTOMS OF PEI

The primary clinical sign of PEI is steatorrhea—loose, fatty, pale, malodorous stool resulting from lipid maldigestion. Unabsorbed fat and oil droplets in stool that stick to the toilet bowl or that are difficult to flush are highly suggestive of PEI. This is a late manifestation of pancreas dysfunction, typically occurring after 90% of exocrine glandular function is lost.¹ Other clinical symptoms that may be suggestive of PEI include malnutrition, growth retardation, or delayed maturation related to nutritional failure; hyperproteinemia with severe edema; decreased muscle mass; and abdominal distension and pain. A small number of patients exhibit fat-soluble vitamin (A, D, E, and K) deficiencies.³⁹ Noticeable digression from weight and height curves plotted during routine pediatric well-visits should also be considered in the context of other symptoms of PEI.⁴⁰ Recent evidence also implicates PEI with associated metabolic bone disease and osteoporosis.⁴¹

Diagnostic Tests To Assess Pancreatic Function

Upon clinical suspicion of pancreatic dysfunction following a complete physical examination, family history, and differential diagnosis, accurate assessment of exocrine function with direct or indirect pancreas function tests is necessary to confirm pancreatic status and initiate appropriate therapy. Pancreas function tests assess pancreatic secretory reserve and are used to diagnose early disease, to monitor disease progression, and to assess the efficacy of PERT in order to

tailor therapy.⁴²⁻⁴⁴ Pancreatic function tests are similar in diagnostic utility across age groups.

Infrequently used in clinical practice, direct (invasive) pancreas function tests require placement of double-lumen gastroduodenal tubes for pancreatic fluid collection following intravenous cholecystokinin (CCK) or secretin stimulation.⁴⁵ The extracted fluid is analyzed quantitatively for enzyme and bicarbonate production. Direct tests are highly accurate for PEI, particularly in early CP, because they detect subtle changes in pancreatic function before the development of overt steatorrhea and morphologic changes observed on imaging tests. Direct tests have been reported to be more than 90% sensitive and specific for detection of PEI.⁴⁵ The major limitations of direct pancreatic function testing have been the cumbersome nature of the test and the difficulty of pancreatic fluid collection with the gastroduodenal tube method.⁴⁶ Thus, they have only been available at select research centers with dedicated gastroenterology laboratory personnel.⁴⁷

Over the past several years, endoscopic collection methods have been developed which have simplified pancreatic fluid collection. These techniques have made the test more suitable for widespread clinical use, including screening patients with chronic pain syndromes for pancreatic disease.^{48,49} With these newer approaches, the upper endoscope is used instead of the gastroduodenal tube to: 1) directly aspirate pancreas fluid (endoscopic pancreatic function testing [ePFT]);⁴⁸ 2) facilitate placement of a modified Dreiling tube (endoscopy-assisted);⁴⁹ or 3) facilitate placement of a Liguory tube.^{50,51} Some centers also directly cannulate the pancreas duct during endoscopic retrograde cholangiopancreatography; this carries some risk for procedure-induced pancreatitis and may not be as accurate as other diagnostic methods.⁵² Furthermore, these newer methods have promoted the use of a hospital autoanalyzer in place of back-titration methods to analyze fluids.^{53,54} Both the application of an endoscopic collection method and the adoption of an autoanalyzer to systematize pancreatic fluid analysis have markedly increased the use of pancreas function testing in the United States.

The ePFT method of direct pancreas fluid aspiration from the duodenum is the most studied and validated endoscopic method of pancreatic function testing.^{55,56} It causes minimal harm to the patient and does not induce pancreatitis. Secretin-, CCK-, and combined secretin-CCK-stimulated ePFT methods have been developed.⁵⁷ Additionally, a shortened “screening” method has been reported to rapidly assess patients with chronic pain syndromes who have a low likelihood of having pancreatic disease.⁵⁸ Aspirated pancreas fluid samples are kept on ice and transported to the hospital laboratory for autoanalyzer analysis of electrolyte and/or enzyme

concentration. Peak pancreas fluid bicarbonate concentrations less than 80 meq/L in the secretin test and peak lipase concentrations less than 780,000 IU/L in CCK-stimulated ePFT are diagnostic of PEI.

In general, investigators have preferentially relied on indirect (noninvasive) methods to circumvent the challenges associated with direct pancreatic function tests. Clinically available indirect tests of pancreatic function include fecal fat analysis, fecal chymotrypsin analysis, acid steatocrit analysis, and fecal elastase analysis.⁵⁹⁻⁶² Most indirect tests are sensitive for moderate- and late-stage PEI but lack sensitivity for early disease detection. However, they are adequate for the assessment of steatorrhea, a manifestation of significant loss of pancreatic function.⁴⁹ The 72-hour fecal fat collection test with calculation of a coefficient of fat absorption is the gold standard for the assessment of fat malabsorption.⁶³ The test requires a 5-day diet of 100 g of fat per day, with stool collections performed throughout the last 72 hours of the diet.⁶³ Fecal fat excretion exceeding 7 g per day is abnormal but not sensitive or specific for PEI, as other gastrointestinal diseases also may be associated with steatorrhea.⁶³ The fecal fat test is inconvenient, unpleasant for patients, and prone to laboratory error and sample loss; therefore, it is primarily used in research settings.⁶³

The fecal elastase-1 test is emerging globally as the most commonly utilized noninvasive test for PEI assessment and also is gaining widespread recognition in the United States.⁶⁴ Elastase-1, a specific protease synthesized by pancreatic acinar cells, is a useful tool for the evaluation of insufficiency because it is stable in stool, unaffected by PERT, and correlates well with stimulated pancreas function tests.⁶⁴ The fecal elastase-1 test is an enzyme-linked immunosorbent assay that uses monoclonal antibodies against two different epitopes of human pancreatic elastase. It has a superior overall diagnostic accuracy when compared with chymotrypsin (92% vs 82%), and measurements may be reproduced for approximately 7 days post-collection.⁶⁴ As with other indirect pancreas function tests, stool dilution can cause false-positive results.⁶⁴ Fecal elastase-1 testing has gained popularity in CF clinics and is now commonly used as evidence of PEI in infants screened for CF to confirm the need for PERT.⁶⁵ Mild and severe PEI diagnoses are based on a fecal elastase-1 value of less than 200 mcg per gram of stool and 100 mcg per gram of stool, respectively.⁶¹

Despite radiologic and endoscopic advances, a diagnostic test that can detect early PEI prior to clinically evident symptoms of steatorrhea is currently unavailable.¹ Diagnostic methods sensitive for early disease are an active area of research and include recent advances in magnetic resonance imaging and secretin-stimulated magnetic resonance cholangiopancreatography

as well as endoscopic ultrasound, which correlate pancreatic function with duct morphology in moderate to advanced disease.^{66,67} Simplification of endoscopic direct function tests as well as further advances in radiologic imaging would potentially offer diagnostic possibilities less cumbersome and better tolerated by patients, thereby broadening the availability and clinical use of direct tests for the early detection of PEI.^{47,68}

Conclusion

Ongoing epidemiologic study is establishing the incidence and prevalence of PEI in the United States and more clearly defining its etiologic risk factors. Despite recent advances in direct pancreas function testing, a point-of-care diagnostic test that can detect early PEI prior to clinically evident symptoms of steatorrhea is still lacking.¹ The patients identified may be started on pancreatic enzyme replacement therapy (PERT) early in the course of the disease in hopes of retarding the complications of long-term malnutrition.

References

1. DiMagno EP, Go VL, Summerskill WH. Relations between pancreatic enzyme outputs and malabsorption in severe pancreatic insufficiency. *N Engl J Med*. 1973;288(16):813-815.
2. Etamad B, Whitcomb DC. Chronic pancreatitis: diagnosis, classification, and new genetic developments. *Gastroenterology*. 2001;120(3):682-707.
3. Domínguez-Muñoz JE. Pancreatic enzyme therapy for pancreatic exocrine insufficiency. *Curr Gastroenterol Rep*. 2007;9(2):116-122.
4. Sarner M. Treatment of Pancreatic Exocrine Deficiency. *World J Surg*. 2003;27(11):1192-1195.
5. Ammann RW, Muellhaupt B. Progression of alcoholic acute to chronic pancreatitis. *Gut*. 1994;35(4):552-556.
6. Lankisch PG, Löhr-Happe A, Otto J, Creutzfeldt W. Natural course in chronic pancreatitis. Pain, exocrine and endocrine pancreatic insufficiency and prognosis of the disease. *Digestion*. 1993;54(3):148-155.
7. Dufour MC, Adamson MD. The epidemiology of alcohol-induced pancreatitis. *Pancreas*. 2003;27(4):286-290.
8. Rosenstein BJ. What is a cystic fibrosis diagnosis? *Clin Chest Med*. 1998;19(3):423-441.
9. Johnson J, Connolly M, Jacobs P, Montgomery M, Brown N, Zuberbuhler P. Cost of care for individuals with cystic fibrosis: a regression approach to determining the impact of recombinant human DNase. *Pharmacotherapy*. 1999;19(10):1159-1166.
10. Cystic Fibrosis Foundation. Median age of survival continues to rise. In: *Commitment*. Spring 2008. Available at: www.cff.org/ECommitment/2008_spring/index.html. Accessed March 30, 2012.
11. Staab D. Cystic fibrosis—therapeutic challenge in cystic fibrosis children. *Eur J Endocrinol*. 2004;151(suppl 1):S77-S80.
12. Choi JY, Muallem D, Kiselyov K, Lee MG, Thomas PJ, Muallem S. Aberrant CFTR-dependent HCO₃-transport in mutations associated with cystic fibrosis. *Nature*. 2001;410(6824):94-97.

13. Durie PR, Forstner GG. Pathophysiology of the exocrine pancreas in cystic fibrosis. *J R Soc Med.* 1989;82(suppl):16:2-10.
14. Koletzko S, Reinhardt D. Nutritional challenges of infants with cystic fibrosis. *Early Hum Dev.* 2001;65(suppl):S53-S61.
15. Schibli S, Durie PR, Tullis ED. Proper usage of pancreatic enzymes. *Curr Opin Pulm Med.* 2002;8(6):542-546.
16. Brunzell C, Schwarzenberg SJ. Cystic Fibrosis-Related Diabetes and Abnormal Glucose Tolerance: Overview and Medical Nutrition Therapy. *Diabetes Spectrum.* 2002;15:124-127.
17. Lowenfels AB, Sullivan T, Fiorianti J, Maisonneuve P. The epidemiology and impact of pancreatic diseases in the United States. *Curr Gastroenterol Rep.* 2005;7(2):90-95.
18. Strausbaugh SD, Davis PB. Cystic fibrosis: a review of epidemiology and pathobiology. *Clin Chest Med.* 2007;28(2):279-288.
19. Lin Y, Tamakoshi A, Matsuno S, et al. Nationwide epidemiological survey of chronic pancreatitis in Japan. *J Gastroenterol.* 2000;35(2):136-141.
20. O'Sullivan JN, Nobrega FT, Morlock CG, Brown AL Jr, Bartholomew LG. Acute and chronic pancreatitis in Rochester, Minnesota, 1940 to 1969. *Gastroenterology.* 1972;62(3):373-379.
21. Uys CJ, Bank S, Marks IN. The pathology of chronic pancreatitis in Cape Town. *Digestion.* 1973;9:454-468.
22. Olsen TS. The incidence and clinical relevance of chronic inflammation in the pancreas in autopsy material. *Acta Pathol Microbiol Scand A.* 1978;86A(5):361-365.
23. Suda K, Shiotsu H, Nakamura T, Akai J, Nakamura T. Pancreatic fibrosis in patients with chronic alcohol abuse: correlation with alcoholic pancreatitis. *Am J Gastroenterol.* 1994;89(11):2060-2062.
24. Lowenfels AB, Maisonneuve P. Epidemiology of chronic pancreatitis. In: Forsmark C, ed. *Pancreatitis and Its Complications.* Totowa, NJ: Humana Press Inc; 2005: 137-147.
25. Lamer P, Yamamoto H, Kalthoff L, Clain JE, Bakken LJ, DiMaggio EP. The different courses of early- and late-onset idiopathic and alcoholic chronic pancreatitis. *Gastroenterology.* 1994;107(5):1481-1487.
26. Lott J, ed. *Clinical Pathology of Pancreatic Disorders.* Totowa, NJ: Humana Press Inc; 1997.
27. Popovic JR, Kozak LJ. National hospital discharge survey: annual summary, 1998. *Vital Health Stat 13.* 2000;(148):1-194.
28. American Gastroenterology Association. Chapter 23: Pancreatitis. In: *National Institute of Diabetes and Digestive and Kidney Diseases—Burden of Digestive Diseases in the United States Educational Slides.* Available at: www.gastro.org/education-meetings/online-education/niddk-burden-of-digestive-diseases-in-the-united-states-educational-slides. Accessed March 30, 2012.
29. Ferrone M, Raimondo M, Scolapio JS. Pancreatic enzyme pharmacotherapy. *Pharmacotherapy.* 2007;27(6):910-920.
30. Lamer P, Holtmann G. Pancreatic enzymes in chronic pancreatitis. *Int J Pancreatol.* 1994;15(1):1-11.
31. Schoonbroodt D, Zipf A, Herrmann G, Jung M. Histological findings in chronic pancreatitis after abdominal radiotherapy. *Pancreas.* 1996;12(3):313-315.
32. DiMaggio EP, Clain JE, Lamer P. Chronic pancreatitis. In: Go VL, et al, eds. *The Pancreas: biology, pathobiology, and diseases.* 2nd ed. New York, NY: Raven Press; 1993: 665-706.
33. Borgström B. Importance of phospholipids, pancreatic phospholipase A2, and fatty acid for the digestion of dietary fat: in vitro experiments with the porcine enzymes. *Gastroenterology.* 1980;78(5 Pt 1):954-962.
34. DiMaggio EP, Malagelada JR, Go VL, Moertel CG. Fate of orally ingested enzymes in pancreatic insufficiency. Comparison of two dosage schedules. *N Engl J Med.* 1977;296(23):1318-1322.
35. Dutta SK, Russell RM, Iber FL. Impaired acid neutralization in the duodenum in pancreatic insufficiency. *Dig Dis Sci.* 1979;24(10):775-780.
36. Holtmann G, Kelly DG, Sternby B, DiMaggio EP. Survival of human pancreatic enzymes during small bowel transit: effect of nutrients, bile acids, and enzymes. *Am J Physiol.* 1997;273(2 Pt 1):G553-G558.
37. Lamer P, Go VL, DiMaggio EP. Fate of pancreatic enzymes during small intestinal aboral transit in humans. *Am J Physiol.* 1986;251(4 Pt 1):G475-G480.
38. Lamer P, Jansen JB, Cherian L, Lamers CB, Goebell H. Feedback regulation of human pancreatic secretion. Effects of protease inhibition on duodenal delivery and small intestinal transit of pancreatic enzymes. *Gastroenterology.* 1990;98(5 Pt 1):1311-1319.
39. Dodge JA, Turck D. Cystic fibrosis: nutritional consequences and management. *Best Pract Res Clin Gastroenterol.* 2006;20(3):531-546.
40. Littlewood JM, Wolfe SP, Conway SP. Diagnosis and treatment of intestinal malabsorption in cystic fibrosis. *Pediatr Pulmonol.* 2006;41(1):35-49.
41. Tignor AS, Wu BU, Whitlock TL, et al. High prevalence of low-trauma fracture in chronic pancreatitis. *Am J Gastroenterol.* 2010;105(12):2680-2686.
42. Niederau C, Grendell JH. Diagnosis of chronic pancreatitis. *Gastroenterology.* 1985;88(6):1973-1995.
43. Conwell DL, Zuccaro G, Morrow JB, et al. Cholecystokinin-stimulated peak lipase concentration in duodenal drainage fluid: a new pancreatic function test. *Am J Gastroenterol.* 2002;97(6):1392-1397.
44. Boyd EJ, Wormsley KG. Laboratory tests in the diagnosis of the chronic pancreatic diseases. Part 2. Tests of pancreatic secretion. *Int J Pancreatol.* 1987;2(4):211-221.
45. DiMaggio MJ, DiMaggio EP. Chronic pancreatitis. *Curr Opin Gastroenterol.* 2003;19(5):451-457.
46. Conwell DL, Zuccaro G Jr, Vargo JJ, et al. An endoscopic pancreatic function test with synthetic porcine secretin for the evaluation of chronic abdominal pain and suspected chronic pancreatitis. *Gastrointest Endosc.* 2003;57(1):37-40.
47. Stevens T, Conwell DL, Zuccaro G, et al. Electrolyte composition of endoscopically collected duodenal drainage fluid after synthetic porcine secretin stimulation in healthy subjects. *Gastrointest Endosc.* 2004;60(3):351-355.
48. Waxman I, Steer ML, Freedman SD. Endoscopically assisted direct pancreatic function testing: a simplified technique. *Gastrointest Endosc.* 1996;44(5):630.
49. Moonsintong P, Burton FR. Pancreatic function testing is best determined by the extended endoscopic collection technique. *Pancreas.* 2008;37(4):418-421.
50. Draganov P, Patel A, Fazel A, Toskes P, Forsmark C. Prospective evaluation of the accuracy of the intraductal secretin stimulation test in the diagnosis of chronic pancreatitis. *Clin Gastroenterol Hepatol.* 2005;3(7):695-699.
51. Draganov P, George S, Toskes PP, Forsmark CE. Is a 15-minute collection of duodenal secretions after secretin stimulation sufficient to diagnose chronic pancreatitis? *Pancreas.* 2004;28(1):89-92.
52. Xiao Z, Lopez R, Parsi MA, Dodig M, Stevens T. Comparison of autoanalyzer and back titration for measurement of bicarbonate concentration in endoscopically collected pancreatic fluid. *Pancreas.* 2011;40(2):237-241.

53. Patel S, Vargo JJ, Khandwala F, et al. Deep sedation occurs frequently during elective endoscopy with meperidine and midazolam. *Am J Gastroenterol*. 2005;100(12):2689-2695.
54. Stevens T, Conwell DL, Zuccaro G Jr, et al. A randomized crossover study of secretin-stimulated endoscopic and dreiling tube pancreatic function test methods in healthy subjects. *Am J Gastroenterol*. 2006;101(2):351-355.
55. Stevens T, Conwell DL, Zuccaro G Jr, et al. A prospective crossover study comparing secretin-stimulated endoscopic and Dreiling tube pancreatic function testing in patients evaluated for chronic pancreatitis. *Gastrointest Endosc*. 2008;67(3):458-466.
56. Stevens T, Dumot JA, Zuccaro G Jr, et al. Evaluation of duct-cell and acinar-cell function and endosonographic abnormalities in patients with suspected chronic pancreatitis. *Clin Gastroenterol Hepatol*. 2009;7(1):114-119.
57. Stevens T, Conwell DL, Zuccaro G Jr, Lewis SA, Love TE. The efficiency of endoscopic pancreatic function testing is optimized using duodenal aspirates at 30 and 45 minutes after intravenous secretin. *Am J Gastroenterol*. 2007;102(2):297-301.
58. Stevens T, Parsi MA. Update on endoscopic pancreatic function testing. *World J Gastroenterol*. 2011;17(35):3957-3961.
59. Jacobson DG, Curington C, Connery K, Toskes PP. Trypsin-like immunoreactivity as a test for pancreatic insufficiency. *N Engl J Med*. 1984;310(20):1307-1309.
60. Lankisch PG. Now that fecal elastase is available in the United States, should clinicians start using it? *Curr Gastroenterol Rep*. 2004;6(2):126-131.
61. Walkowiak J, Nousia-Arvanitakis S, Cade A, et al. Fecal elastase-1 cut-off levels in the assessment of exocrine pancreatic function in cystic fibrosis. *J Cyst Fibros*. 2002;1(4):260-264.
62. Walkowiak J, Herzig KH, Strzykala K, Przyslawski J, Krawczynski M. Fecal elastase-1 is superior to fecal chymotrypsin in the assessment of pancreatic involvement in cystic fibrosis. *Pediatrics*. 2002;110(1 Pt 1):e7.
63. Borowitz D. Update on the evaluation of pancreatic exocrine status in cystic fibrosis. *Curr Opin Pulm Med*. 2005;11(6):524-527.
64. Carroccio A, Verghi F, Santini B, et al. Diagnostic accuracy of fecal elastase 1 assay in patients with pancreatic maldigestion or intestinal malabsorption: a collaborative study of the Italian Society of Pediatric Gastroenterology and Hepatology. *Dig Dis Sci*. 2001;46(6):1335-1342.
65. Cade A, Walters MP, McGinley N, et al. Evaluation of fecal pancreatic elastase-1 as a measure of pancreatic exocrine function in children with cystic fibrosis. *Pediatr Pulmonol*. 2000;29(3):172-176.
66. Balci NC, Alkaade S, Magas L, Momtahan AJ, Burton FR. Suspected chronic pancreatitis with normal MRCP: findings on MRI in correlation with secretin MRCP. *J Magn Reson Imaging*. 2008;27(1):125-131.
67. Czako L. Diagnosis of early-stage chronic pancreatitis by secretin-enhanced magnetic resonance cholangiopancreatography. *J Gastroenterol*. 2007;42(suppl 17):113-117.
68. Conwell DL, Zuccaro G, Purich E, et al. The effect of moderate sedation on exocrine pancreas function in normal healthy subjects: a prospective, randomized, cross-over trial using the synthetic porcine secretin stimulated Endoscopic Pancreatic Function Test (ePFT). *Am J Gastroenterol*. 2005;100(5):1161-1166.
69. Fieker A, Philpott J, Armand M. Enzyme replacement therapy for pancreatic insufficiency: present and future. *Clin Exp Gastroenterol*. 2011;4:55-73.

AUTHOR DISCLOSURES—Ms. Suleiman and Dr. Conwell have no conflicts of interest. Dr. Kadiyala did not report any conflicts of interest.

DISCLAIMER—This review is designed to be a summary of information and represents the opinions of the author(s). Although detailed, the review is not exhaustive. Readers are strongly urged to consult any relevant primary literature, the complete prescribing information available in the package insert of each drug, and the appropriate clinical protocols. No liability will be assumed for the use of this review, and the absence of typographical errors is not guaranteed. Copyright © 2012, McMahon Publishing, 545 West 45th Street, 8th Floor, New York, NY 10036. Printed in the USA. All rights reserved, including right of reproduction, in whole or in part, in any form.

Thank You

for consistently making

Gastroenterology & Endoscopy News

the **best-read** publication in the
U.S. gastroenterology market

**More than 17,000 readers*
every month:**

- ◆ 13,477 gastroenterologists
- ◆ 1,532 colon and rectal surgeons
- ◆ 982 pediatric gastroenterologists
- ◆ 798 physician assistants
- ◆ 219 nurse practitioners
- ◆ 109 hepatologists



#1 in readership[†],
including:

- ◆ high readers
- ◆ average issue readers
- ◆ 4/4 (monthly) readers
- ◆ cover-to-cover readers

* BPA Worldwide, July 2011

† Kantar Media, December 2011